SRPK1 acetylation modulates alternative splicing to regulate cisplatin resistance in breast cancer cells

Cisplatin and other platinum-based compounds are frequently used to treat breast cancer, but their utility is severely compromised by drug resistance. Many genes dictating drug responsiveness are subject to pre-mRNA alternative splicing which is regulated by key kinases such as the serine-arginine p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Cheng, Zhou, Zhihong, Subhramanyam, Charannya Sozheesvari, Cao, Qiong, Heng, Zealyn Shi Lin, Liu, Wen, Fu, Xiangdong, Hu, Qidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253463/
https://www.ncbi.nlm.nih.gov/pubmed/32461560
http://dx.doi.org/10.1038/s42003-020-0983-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253463/
https://www.ncbi.nlm.nih.gov/pubmed/32461560
http://dx.doi.org/10.1038/s42003-020-0983-4

Ejemplares similares